RxDoctor Payments Data

Steve Shah, MD

Family Medicine · Middletown, NYNPI 1073133765

Payments from drug & device makers

$1,715in general payments, 2019–2025

Across 59 payments — averaging $29.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$292
  • Bayer$276
  • Novo Nordisk$228
  • Medtronic$156
  • Exact Sciences$122
  • Vivus LLC$120
  • plus $520 from 14 others

What the payments were for

  • Food & beverage$1,69199%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,715 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$80,675
Medicare patients
261
Services billed
2,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide74$76,370
OzempicSemaglutide27$24,695
XareltoRivaroxaban18$12,804
JardianceEmpagliflozin12$10,832
Atorvastatin Calcium38$376
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav39$257
Ofloxacin11$241
Ezetimibe18$235
Methylprednisolone30$204
Doxycycline Hyclate30$185
Famotidine12$139
Metformin Hcl33$131
Fluticasone Propionate17$124
Mupirocin12$83
Prednisone39$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$44$76,37074 claims
Novo NordiskOzempic$228$24,69527 claims
Johnson & JohnsonXarelto$33$12,80418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →